GSK plc (GSK) Stock Score, Valuation & Financial Research
GSK plc is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 45/100.
Quick answer for GSK
GSK plc currently has a Wall Street Score of 45/100. The stored market price is $48.13. Its financial score is 26/100. Its valuation score is 54/100. The latest WSS change is -14.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What GSK plc does
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunolo
GSK financial snapshot
- Wall Street Score:
- 45/100
- Current price:
- $48.13
- Market capitalization:
- $96.43B
- Revenue:
- $44.79B
- Net income:
- $6.50B
- Free cash flow:
- $7.86B
- Cash:
- $4.16B
- Total debt:
- $24.46B
- EPS:
- 3.80
- P/E ratio:
- 12.7x
- Financial score:
- 26/100
- Valuation score:
- 54/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $7.86B, showing positive cash generation.
- The balance sheet shows $4.16B of cash versus $24.46B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -14.4 points: GSK decreased 14.4 points because Asset declined by 5.7 points, Capital declined by 10 points, Management declined by 5 points.
What the numbers mean
Its current valuation score is 54/100, which Wall Street Score classifies as mixed within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GSK
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.